TY  - CHAP
M1  - Book, Section
TI  - CARDIAC TRANSPLANTATION
A1  - Kittleson, Michelle M.
A1  - Patel, Jignesh K.
A1  - Kobashigawa, Jon A.
A2  - Fuster, Valentin
A2  - Harrington, Robert A.
A2  - Narula, Jagat
A2  - Eapen, Zubin J.
PY  - 2017
T2  - Hurst's The Heart, 14e
AB  - Despite  major  advances  in  the  treatment  of  end-stage  heart  disease,  a  sizable  number  of  patients  with  refractory  heart  failure  (HF),  progressive  angina,  or  uncontrolled  ventricular  arrhythmias  cannot  be  stabilized  with  medical  or  interventional/surgical  therapy  and  suffer  significant  morbidity  and  mortality.1  In  these  patients,  biological  replacement  of  the  heart  (cardiac  transplantation)  has  become  standard  therapy  and  is  widely  accepted  to  improve  quality  and  quantity  of  life  in  carefully  selected  patients.  As  technologic  and  engineering  advances  occur,  support  or  replacement  of  the  heart  by  mechanical  devices  (mechanical  circulatory  support  [MCS])  offers  additional  options  for  patients  with  end-stage  heart  disease  as  a  bridge  to  recovery,  bridge  to  transplantation,  or  destination  therapy.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1161716891
ER  -